EYPT EyePoint Pharmaceuticals Inc
Price (delayed)
$8.93
Market cap
$477.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.78
Enterprise value
$409.16M
EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a
Highlights
EYPT's gross profit has surged by 53% year-on-year
The EPS has grown by 37% YoY
EYPT's quick ratio has surged by 104% year-on-year but it is down by 6% since the previous quarter
The net income rose by 18% year-on-year but it has declined by 10% since the previous quarter
EYPT's equity is down by 9% since the previous quarter
Key stats
What are the main financial stats of EYPT
Market
Valuations
Earnings
Shares outstanding
53.52M
Market cap
$477.92M
Enterprise value
$409.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.04
Price to sales (P/S)
9.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.12
Revenue
$50.39M
EBIT
-$86.74M
EBITDA
-$85.85M
Free cash flow
-$94.36M
Per share
Balance sheet
Liquidity
EPS
-$1.78
Free cash flow per share
-$1.77
Book value per share
$4.38
Revenue per share
$0.95
TBVPS
$6.09
Total assets
$324.25M
Total liabilities
$95.94M
Debt
$22.16M
Equity
$228.31M
Working capital
$232.83M
Debt to equity
0.1
Current ratio
4.75
Quick ratio
4.54
Net debt/EBITDA
0.8
Margins
Efficiency
Dividend
EBITDA margin
-170.4%
Gross margin
91.3%
Net margin
-172.3%
Operating margin
-195.7%
Return on assets
-29.7%
Return on equity
-43.2%
Return on invested capital
-195.9%
Return on capital employed
-33.1%
Return on sales
-172.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EYPT stock price
How has the EyePoint Pharmaceuticals stock price performed over time
Intraday
1.71%
1 week
8.64%
1 month
12.61%
1 year
-7.56%
YTD
-61.36%
QTD
2.64%
Financial performance
How have EyePoint Pharmaceuticals's revenue and profit performed over time
Revenue
$50.39M
Gross profit
$46.03M
Operating income
-$98.62M
Net income
-$86.82M
Gross margin
91.3%
Net margin
-172.3%
EYPT's gross profit has surged by 53% year-on-year
The net margin has increased by 39% year-on-year but it has declined by 9% since the previous quarter
The revenue has increased by 35% year-on-year
The company's operating margin rose by 31% YoY but it fell by 13% QoQ
Growth
What is EyePoint Pharmaceuticals's growth rate over time
Valuation
What is EyePoint Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.04
P/S
9.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.12
The EPS has grown by 37% YoY
The stock's price to book (P/B) is 65% less than its 5-year quarterly average of 5.7 and 43% less than its last 4 quarters average of 3.5
EYPT's equity is down by 9% since the previous quarter
EYPT's P/S is 36% below its last 4 quarters average of 14.5 but 12% above its 5-year quarterly average of 8.3
The revenue has increased by 35% year-on-year
Efficiency
How efficient is EyePoint Pharmaceuticals business performance
EyePoint Pharmaceuticals's ROE has soared by 62% YoY and by 13% from the previous quarter
EYPT's return on assets is up by 49% year-on-year and by 3.9% since the previous quarter
The ROS has grown by 38% YoY but it has contracted by 10% from the previous quarter
The ROIC is down by 26% YoY
Dividends
What is EYPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EYPT.
Financial health
How did EyePoint Pharmaceuticals financials performed over time
EYPT's quick ratio has surged by 104% year-on-year but it is down by 6% since the previous quarter
EyePoint Pharmaceuticals's current ratio has soared by 96% YoY but it has decreased by 6% from the previous quarter
The debt is 90% smaller than the equity
EYPT's equity is down by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.